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Abstract: Morniga-G, the Gal-specific black mulberry (Morus nigra) lectin, displays high affinity for
T (CD176) and Tn (CD175) antigens, frequently expressed at the cancer cell surface. The effects
of Morniga-G were investigated on a Tn-positive leukemic Jurkat cell line. The lectin, used
in a concentration range between 5–20 µg/mL, induced cell death in leukemic Jurkat cells.
Microscopic and cytofluorometric analyses indicated that Jurkat cell death was essentially apoptotic,
associated with an increase in the ceramide content and a depolarization of the mitochondrial
transmembrane potential. This lectin-mediated cell death was inhibited by the pan caspase-inhibitor
zVAD. In addition, cleavage of caspases 8, 9, and 3 was observed in Morniga-G-treated Jurkat cells
whereas Jurkat cell lines that are deficient in caspase 8–10, caspase 9, or FADD, survived to the
lectin-mediated toxicity. Furthermore, in the presence of TRAIL- or DR5-blocking mononoclonal
antibodies, Jurkat cells became resistant to Morniga-G, suggesting that the lectin triggers cell death
via the TRAIL/DR5 pathway. In silico computer simulations suggest that Morniga-G might facilitate
both the DR5 dimerization and the building of TRAIL/DR5 complexes. Finally, upon treatment of
Jurkat cells with benzyl-GalNAc, an O-glycosylation inhibitor, a decrease in Tn antigen expression
associating with a reduced Morniga-G toxicity, was observed. Taken together, these results suggest
that Morniga-G induces the cell death of Tn-positive leukemic cells via concomitant O-glycosylation-,
caspase-, and TRAIL/DR5-dependent pathways.
Keywords: plant lectin; Morniga-G; O-glycosylation; T/Tn antigen; Jurkat cells; cancer cell death;
apoptosis; TRAIL/DR5 pathway
1. Introduction
Glycosylation is known to contribute to different recognition and activation cell events
but also to the cell death processes, altogether occurring during normal functioning of the
cellular immune system [1–4]. Previous results demonstrated that plant lectins displaying
very similar monosaccharide-binding specificity and three-dimensional structure differ in their
capacity to recognize subtle alterations in the glycosylation induced by the lymphocyte activation
process [5]. In this respect, two closely structurally-related Man-specific lectins, artocarpin from
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Artocarpus integrifolia [6] and Morniga-M from Morus nigra [7], both activate human resting
T-lymphocytes but only Morniga-M induces cell death of activated T cells [5]. This observation suggests
that Morniga-M, in addition to recognizing glycan structures associated to proliferative signaling
pathway(s), might also interfere with glycan structures involved in the cell death signaling pathway(s).
Aberrations in the glycosylation processes have been reported to occur frequently in tumor
cells. Truncation of the O-glycan chains at the cell surface of cancer cells result in the formation of T
(Galβ1-3GalNAcα1-O-Ser/Thr, i.e., CD176) and Tn (GalNAcα1-O-Ser/Thr, i.e., CD175) antigens [8–12].
In healthy cells, Tn and T consist of the first and second step in the O-glycosylation biosynthesis
pathway, respectively, just before a further elongation giving longer Gal/GalNAc-containing O-glycans.
Both types of tumor-associated carbohydrate antigens (TACAs) have been identified in 70–90% of
colon, stomach, bladder, lung, ovary, prostate, and cervix cancers whereas they have not been, or only
slightly, expressed in healthy tissues and organs [9,10,12]. Morniga-G, the Gal/GalNAc-specific lectin
from black mulberry, displays high affinity for both T and Tn antigens, in cell-free systems [13].
Leukemic Jurkat A3 cells, which expose a major proportion of Tn antigen at the cell surface,
associated to a minor amount (17%) of more complex O-glycans, represent an ideal model for studying
the defect in the O-glycosylation inititiation associated to cancer cells [14]. The O-glycosylation
alterations occurring in Jurkat cells basically depend on the mutation of core 1 β3-Gal-T-specific
molecular chaperone (Cosmc), that inhibits the C1β3Gal-T activity and the further addition of Gal
to the Tn antigen [15]. We previously demonstrated that Morniga-G was specifically and quickly
taken-up by Tn positive leukemia Jurkat T cells but not by Tn negative normal T lymphocytes [16].
Accordingly, Morniga-G covalently coupled to a photosensitizer was successfully used to design
conjugates for anticancer phototherapy that was susceptible to specifically target the O-glycosylation
alterations of tumor cells. An in vitro evaluation of these conjugates, used at 15–30 nM concentrations,
readily improved the drug endocytosis and phototoxicity (by a factor 1000) in various tumor cells [17].
However, in our in vitro experiments, unconjugated Morniga-G displayed a toxic activity on Jurkat T
cells at 1 mM concentration, irrespective of the photo-irradiation of the cells.
Being a component of the extrinsic apoptotic pathway, the Tumor Necrosis Factor (TNF) -related
apoptosis-inducing ligand (TRAIL) specifically interacts with DR4 (TRAIL receptor-1) and/or DR5
(TRAIL receptor-2), to recruit the Fas-associated adaptor protein with a death domain (FADD),
which binds to the procaspase-8 or procaspase-10 to create the death-inducing signaling complex
(DISC). Both DR4 (CD261) and DR5 (CD262) possess four to five potential O-glycosylation sites,
and mutations in the DR5 were previously reported to inhibit the TRAIL-mediated apoptosis,
suggesting that O-glycosylation of the TRAIL/DR5 complex controls the sensitivity of tumor cells to
the preapoptotic TRAIL ligand [18].
In the present work, the toxic effects of the Tn-specific plant lectin Morniga-G, were checked on
leukemia Jurkat T cells, which present an impairment in the O-glycosylation, i.e., a strong expression of
Tn antigen [12], and express the TRAIL receptor DR5 [19]. Our results suggest that the cancer-induced
defects in DR5 O-glycosylation occurring in Jurkat T cells, could serve as a target for Morniga-G for
inducing cell death via the TRAIL signaling pathway.
2. Results
2.1. Morniga-G activates T, B, and NK Lymphocytes and Induces Cell Death in Tn Positive Leukemia
Lymphocytes
Plant lectins with different monosaccharide-binding specificities, e.g., the Man/Glc-specific Con A
and the GlcNAc-specific pokeweed (Phytolacca americana) mitogen PWM, are known for a long time to
readily activate resting lymphocytes. The in vitro effect of Gal/GalNAc/Tn-specific lectin Morniga-G
was evaluated on resting human lymphocytes, and results were compared to Con A and Morniga-M,
the Man-specific lectin from Morus nigra. Morniga-G induced the proliferation of 3-day-old cultured
Peripheral blood mononuclear cells (PBMCs) at a concentration ranging between 2.5 and 25 µg/mL,
with an optimal effect at 10 µg/mL (Figure 1A).
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concentrations of Morniga-M (MorM), Morniga-G (MorG), and Con A and proliferative index (from 
the [3H]-thymidine incorporation) was calculated; and (B) in the presence of lectins at concentrations 
triggering maximal proliferation. CD25 expression was evaluated using flow cytometry, in CD3+ T 
lymphocytes, in CD19+ CD3- B lymphocytes, and in CD56+ CD3- NK lymphocytes. Values are means 
± SD of three experiments performed with three to four different healthy donors. (C) Resting PBMCs 
and Jurkat A3 leukemic cells were incubated with anti-Tn mouse monoclonal antibody + 
PE-conjugated anti-mouse antibody (αTn + antiα-PE) or FITC-conjugated Morniga G (MorG-FITC) 
and analyzed using cytofluorimetry. Healthy peripheral lymphocytes (PBLs) were analyzed in a gate 
corresponding to lymphocytes as defined by the size and granularity parameters. Autofluorescence: 
purple histograms, dashed green histogram: fluorescent positive cells. (D) PBMCs of healthy donors 
and Jurkat A3 leukemic cells were cultured for 24 h with different concentrations of MorG, then cell 
viability was evaluated in 3-(4,5-dimethylthiazol)-2-5-diphenyl terazolium bromide MTT reduction 
assays (mean values ± SD of four independent experiments). 
A similar proliferative effect was observed with Con A. In contrast, 10 μg/mL Morniga-M 
dramatically decreased the thymidine incorporation, compared to the rather limited decrease 
observed for Morniga-G and Con A. Expression of CD25 measured by cytofluorometric analysis on 
T, B, and NK lymphocyte populations after 3 days of cultivation in the presence of lectin 
concentrations yielding the higher rate of proliferation, showed that Morniga-G preferentially 
activated B cells, whereas both of the other lectins triggered a similar CD25 expression in T and NK 
cells (Figure 1B). 
Figure 1. Morniga-G activates healthy human lymphocytes and induces cell death in leukemia cells.
PBMCs from healthy donors were cultured for 3 days: (A) in the presence of increasing concentrations of
Morniga-M (MorM), Morniga-G (MorG), and Con A and proliferative index (from the [3H]-thymidine
incorporation) was calculated; and (B) in the presence of lectins at concentrations triggering maximal
proliferation. CD25 expression was evaluated using flow cytometry, in CD3+ T lymphocytes, in CD19+
CD3- B lymphocytes, and in CD56+ CD3- NK lymphocytes. Values are means± SD of three experiments
performed with three to four different healthy donors. (C) Resting PBMCs and Jurkat A3 leukemic
cells were incubated with anti-Tn mouse monoclonal antibody + PE-conjugated anti-mouse antibody
(αTn + antiα-PE) or FITC-conjugated Morniga G (MorG-FITC) and analyzed using cytofluorimetry.
Healthy peripheral lymphocytes (PBLs) were analyzed in a gate corresponding to lymphocytes as
defined by the size and granularity parameters. Autofluorescence: purple histograms, dashed green
histogram: fluorescent positive cells. (D) PBMCs of healthy donors and Jurkat A3 leukemic cells
were cultured for 24 h with different concentrations of MorG, then cell viability was evaluated in
3-(4,5-dimethylthiazol)-2-5-diphenyl terazolium bromide MTT reduction assays (mean values ± SD of
four independent experiments).
A similar proliferative effect was observed with Con A. In contrast, 10 µg/mL Morniga-M
dramatically decreased the thymidine incorporation, compared to the rather limited decrease observed
for Morniga-G and Con A. Expression of CD25 measured by cytofluorometric analysis on T, B, and NK
lymphocyte populations after 3 days of cultivation in the presence of lectin concentrations yielding the
higher rate of proliferation, showed that Morniga-G preferentially activat d B cells, whereas both of
th other lectins triggered a similar CD25 expression in T and NK cells (Figure 1B).
Compared to healthy peripheral blood lymphocytes (PBLs), Jurkat lymphoid leukemic cells
highly express Tn antigen at the cell surface (Figure 1C) and, accordingly, a correlation was observed
between the Tn expression level in both types of cells and the binding of Morniga-G, as shown from
cytofluorometric measurements (Figure 1C). Moreover, after a 24 h-cultivation period in the presence
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of Morniga-G at concentrations ranging from 5 to 20 µg/mL, a substantial decrease of cellular viability
was observed in Jurkat cells, whereas the growth of PBMCs was not affected (Figure 1D).
2.2. Morniga-G Induces Caspase-Dependent Cell Death in Tn-Positive Jurkat Cells
The microscopic examination of the Morniga-G-treated Jurkat A3 cells after staining with Syto13 +
propidium iodide, revealed the morphological changes typical for apoptosis in the majority of the cells,
together with a minority of necrotic morphologies, that suggests that several cell death mechanisms
are concomitantly activated after treatment of Jurkat cells with the lectin (Figure 2A).
Evaluating the cleavage of caspase-3, 8, 9, and Poly (ADP-Ribose) polymerase (PARP), in western
blot experiments, revealed a cleavage of caspase-3 and PARP after 6 h of incubation in Morniga-G
treated Jurkat cells, whereas the cleavage of other caspases 8 and 9 occurred later (Figure 2B). This result
suggests that a caspase-3-dependent signaling pathway becomes rapidly activated upon treatment
with the lectin. In addition, the Morniga-G-induced cell death was significantly inhibited in Jurkat cells
previously cultured in the presence of the caspase inhibitor z-VAD (Figure 2C), suggesting Morniga-G
is capable of activating signaling pathways involving different caspases to induce Jurkat cell death.
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Figure 2. Analysis of Morniga-G-induced cell death in Jurkat leukemic cells. Jurkat A3 leukemic cells 
were incubated for 24 h with MorG (20 μg/mL), then analyzed using (A) fluorescence microscopy 
after Syto13 (green fluorescence) + propidium iodide staining (red fluorescence), Scale bars = 10 μm, 
(B) western blotting after staining with various anti-caspases and anti-PARP mAbs, and (C) 
cytofluorometry after Propidium iodide PI + FITC-annexin staining or MTT assays. (A,B) are 
representative of three identical experiments, (A) c and d show apoptotic cells whereas e and f show 
necrotic cells. (C) Cells were incubated with MorG in the presence of absence of z-VAD-fmk, a 
Figure 2. Analysi of or i ced cell death in Jurkat leukemic cells. Jurkat A3 leuk mic
cells were incubated for 24 with MorG (20 µg/mL), then analyzed sing (A) fluorescence
microscopy after Syto13 (gre fluorescence) + propidium iodide staining (r d fluorescence), Scale
bars = 10 µm, (B) western blotting after staining with various anti-caspases and anti-PARP mAbs,
and (C) cytofluorometry after Propidium iodide PI + FITC-annexin staining or MTT assays. (A,B) are
representative of three identical experi ents, (A) c and d show apoptotic cells whereas e and f
show necrotic cells. (C) Cells were incubated with MorG in the presence of absence of z-VAD-fmk,
a cell-permeant pan-caspase inhibitor: (1) cytofluorometric representative experiment, (2) MTT assays,
(3) PI + FITC-annexin staining. Results are mean ± SD of three independent experiments, * p < 0.05.
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2.3. MorG Activates Different Steps of Extrinsic and Intrinsic Pathways of Caspase-Dependent Cell Apoptosis
in Tn-Positive Jurkat Cells
To check the involvement of caspase-9 in Morniga-G-induced cell death, experiments were carried
out with ∆9 Jurkat cells, a cell line characterized by a genetic deficiency in caspase-9. The absence of
caspase-9 readily protected the leukemia ∆9 Jurkat cells from Morniga-G-induced cell death (Figure 3A).
In addition, an evaluation of the membrane potential of the mitochondria by cytofluorimetry, showed
that death of the Jurkat A3 cells was accompanied by a reversal in the mitochondrial membrane
potential (Figure 3B). Finally, the amount of ceramides produced in Jurkat cells as an effect of
Morniga-G treatment exhibited a marked increase in these molecules, which are known to participate
in the activation of the intrinsic pathway of the caspase-induced cell apoptosis (Figure 3C).
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Figure 3. Morniga-G-induced cell death involves mitochondria, ceramides and caspase 9
(intrinsic pathway). Jurkat A3 leukemia cells were incubated for 24 h wit MorG (20 µg/mL).
(A) MorG-mediated toxicity was evaluated by MTT assay (% of viable cells) or by annexin/PI IP
and cytofluorometry (% of annexin-positive cells), in Jurkat parental leukemia cells (A3) and in
caspase 9-deficient Jurkat cells (∆9) treated with MorG (20 µg/mL). Results are mean ± SD of
three independent experiments, * p < 0.05. (B) Apoptosis and mitochondrial membrane potential
(mitopotential), representative of two duplicate experiments, were analyzed using cytofluorometry in
Jurkat A3 cells. (C) Total ceramide content measured in Morniga-G treated Jurkat A3 cells. Results are
mean ± SD of three independent experiments.
Similarly, double-deficient cells for caspase 8 and 10, and FADD-deficient Jurkat cells,
were cultured in the presence of 20 µg/mL of Morniga-G for 24 h. Caspase inhibitor zVAD was
added in non-deficient Jurkat A3 cells, as a cell death inhibitory control. In these experimental
conditions, as previously reported, Jurkat cells were protected against MorG-induced cell death via
zVAD addition, whereas the absence of FADD or caspases 8/10 had also a strong protective effect
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on cell viability (Figure 4A, left). Evaluating cell death using cytofluorometric analysis suggested,
however, that Morniga-G might induce cell death via FADD- and caspases 8,10- independent pathways,
in a minor proportion of cells (Figure 4A, right).
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Figure 4. Morniga-G-induced cell death involves caspase-dependent extrinsic pathway. (A) Jurkat
leukemic cells (A3) with or without zVAD, FADD-deficient Jurkat cells (∆ FADD), and Caspases 8- and
10-deficient Jurkat cells (∆ casp 8–10) were cultured for 24 h with or without Morniga-G (20 µg/mL).
Cytotoxicity was evaluated using an MTT assay (cell viability in percentage of controls without MorG,
mean ± SD of four independent experiments, * p < 0.05) or using annexin/IP and cytofluorometry
(MorG-induced cell death, i.e., annexin positivity after subtraction of cell death percentage in control
cells without MorG, mean ± SD of 3 independent experiments). (B) Jurkat A3 leukemic cells were
cultured for 24 h with or without Morniga-G (20 µg/mL) or TRAIL cytokine (50 ng/mL), and with or
without DR5 (αDR5) or TRAIL (αTRAIL) blocking monoclonal antibodies. Cytotoxicity was evaluated
using an MTT assay (left panel, % of viable cells, mean ± SD of four independent experiments,
* p < 0.05) or using annexin/IP and a cytofluorometry assay (right panel, cell death percentage, mean
± SD of three independent experiments, * p < 0.05).
Since FADD is involved in death receptor-mediated pathways of cell apoptosis and necroptosis
triggered by cytokines like TRAIL, TNF, or FasL [20], cytotoxicity experiments were performed in
the presence of Morniga-G and compared to TRAIL-mediated toxic effects. Jurkat cells are known
to be TRAIL sensitive and express DR5, the TRAIL-receptor 2 [19]. As expected, both Morniga-G
and TRAIL had cytotoxic effects on Jurkat A3 cells, as measured after a 24-h culture (Figure 4B).
The TRAIL-mediated cell death was almost completely inhibited when blocking monoclonal antibodies
against DR5 or TRAIL were added separately to the cell cultures.
However, addition of the blocking monoclonal antibodies only partially protected the
Morniga-G-treated cells (Figure 4B, left). Finally, the simultaneous addition of both blocking antibodies
resulted in a complete inhibition of TRAIL-induced cell death, whereas Morniga-G-treated cells still
remained only partially protected (Figure 4B, right). These results suggest that Morniga-G induces cell
death via, at least in part, an activation of the TRAIL/DR5 signaling pathway.
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2.4. The O-Glycosylation at the Leukemic Cell Surface Is Involved in Morniga-G Induced Cell Death
Owing to the previously observed correlation between the binding of Morniga-G to Jurkat cells
and their Tn-expression level (Figure 1), the role of surface-exposed O-glycans in the Morniga-G
cytotoxicity was further investigated. Cytofluorometric experiments aimed at evaluating the
effects of benzyl-GalNAc, an O-glycosylation inhibitor, on both the DR5/Tn expression and the
Morniga-G-induced Jurkat cell death, showed stable expression of DR5 on the inhibitor-treated
Jurkat cells (Figure 5A). Conversely, a decrease in both the Tn expression and the binding of
Morniga-G at the cell surface was observed in the inhibitor-treated Jurkat cells (Figure 5A). In addition,
those cells expressing low levels of Tn antigen exhibited enhanced resistance to the Morniga-G-induced
cytotoxicity, most probably as a consequence of the inhibition of Tn expression. In contrast, partial
inhibition of O-glycosylation did not cause a decrease in cell death, neither in TRAIL-treated nor in
FasL-treated Jurkat cells (Figure 5B). Taken together, these results suggest that Morniga-G-induced cell
death in Jurkat cells is associated with O-glycosylation and, most probably, depends on the level of
expression of Tn antigen at the cell surface.
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the cells were analyzed: (A) using cytofluorometry after staining with FITC-conjugated MorG
(MorG-FITC), anti-Tn mouse monoclonal antibody + Phycoerythrin PE-conjugated anti-mouse antibody
(αTn + antiα-PE) or PE-conjugated anti-DR5 monoclonal antibody (α DR5-PE). Histograms overlay,
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annexin/IP staining. Cell viability is shown as percentage of annexin- and IP-negative cells after
a 24 h culture in presence of MorG (20 µg/mL), TRAIL (50 ng/mL), or FasL (50 ng/mL). Mean of
two independent experiments.
As previously described (Protein Data Bank code 1DU3), the extracellular domain of the
TRAIL-DR5 complex consists of three DR5 monomers tightly associated by non-covalent bonds to the
TRAIL homotrimer, to form a symmetric ligand-receptor complex [20–22]. Since DR5 contains several
putative sites of O-glycosylation—namely Ser74, Ser75, and Ser77, and Thr130, Thr131, Thr132, Thr135,
and Thr143, respectively (Figure 6A)—it is tempting to speculate that Tn antigen molecules probably
expressed at Ser and/or Thr residues of DR5 can serve as possible ligands for the four Tn-specific
binding sites of Morniga-G (Figure 6B,D). In order to reinforce this hypothesis, docking experiments
performed between the three-dimensional model built for Morniga-G and the crystallographic complex
TRAIL-DR5 (PDB code 1DU3), suggested a possible interaction between Morniga-G and several
Tn-containing Ser or Thr residues of DR5 (Figure 6C). Moreover, these Tn-mediated interactions
between Morniga-G and the TRAIL-DR5 complexes, could facilitate in some way the dimerization
and oligomerization process occurring between the TRAIL-DR5 complexes at the surface of Jurkat
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cells. In this respect, the well-exposed Tn antigens associated to both Thr130 and Thr131 residues,
could play a key role in the binding of Morniga-G to create transient molecular bridges important
to facilitate the dimerization/oligomerization of the TRAIL-DR5 complexes (Figure 7). However,
while this hypothesis is attractive, it remains fully speculative and, obviously, additional experiments
will be necessary in future either rebut or confirm its reality.
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TRAIL/DR5 complexes (TRAIL trimers in green/DR5 in purple) via the specific recognition of Tn
antigen associated to Thr131 (colored pink) of DR5 monomers. Similarly, the lectin could facilitate the
aggregation of the TRAIL/DR5 complexes via specific interactions with Tn antigen associated to Thr
130 of DR5.
3. Discussion
As shown from our results, Morniga-G, a Gal/GalNAc- and Tn-specific lectin, readily activated
healthy lymphocytes to trigger cell proliferation and asso i te CD25 expression (Figure 1A,B),
w re both events ar considered as the first step i the lymphoid activation [23]. However, sting
lymphocytes were ch acterized as Tn-negative cells and only moderately interacted with Morniga-G,
compared to Tn-positive Ju ka cells, which heavily int racted with the ectin. Accordingly, the mitogen
activity of Morniga-G-binding on resting lymphocytes most probably relies on the presence of
Gal/GalNac residues in some ator glyc proteins and glycolipid , which are sufficiently accessible
at the cell surface to interact with the lectin, as previously reported for other lecti s [24].
Both Ma -specific lectins Con A and Morniga M triggered e activa ion of T and NK lym hocytes.
Interestingly, Morniga-G strongly activated B-lymphocytes, similar to the pokeweed mitogen (PWM),
which also activates B-lymphocytes and T-lymphocytes as well [25]. However, human peripheral blood
B-lymphocytes cultured with PWM in the absence of other cells were unable to proliferate, and their
activation was dependent on the presence of accompanying T cells and monocytes [25]. Since (1)
monocytes account for 10–20% of the PBMCs used in our experiments, and (2) Morniga-G binds
equally well to bot onocytes and lymphocytes (results not shown), activation of B lymphocyt s
by Morniga-G most probably depends on cooperation between previously lectin-activated T cells
and monocytes, e.g., by induction of IL-6 secretion, a B cell-activating, and proliferative cytokine.
Finally, the Gal/GalNAc-specific lectin Morniga-G, can activate healthy T and NK cells, similar to the
Man/Glc-specific C n A, and also B cells, similarly to the lcNAc specific PWM. In agree ent with
previous observations, the present results suggest that lectins with different monosaccharide-binding
specificities may recognize subtle differences in the oligosaccharide patterns occurring at the surface
of activation molecules, to trigger the effective activation of lymphocytes. As with Con A, PHA
(Phytohemagglutinin from Phaseolus vulgaris), or PWM, the activation by Morniga-G probably involves
the specific recognition of oligosaccharide p tterns carried by CD molecules involved in lymphoid
activation, e.g., CD3, CD45, or CD79 molecules.
It is well established that carcinogenesis is associated with changes in the cell glycome, such as
the expression of an aberrant O-glycosylation [8–12]. These modifications in the O-glycosylation
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are most likely involved in various tumoral processes, e.g., the epithelial to mesenchymal transition
(EMT) and the formation of metastasis [26–28]. The occurrence of truncated O-glycan chains in
the form of T or Tn antigens, is one of the modifications frequently encountered at the surface of
tumor cells [9–12]. A number of Gal/GalNAc-binding lectins from plants and fungi can specifically
interact with O-glycans occurring at the cell surface, and potentially induce cell function alterations.
In addition, a few Gal/GalNAc-specific lectins recognize T and Tn antigens with a high affinity,
e.g., PNA from peanuts, jacalin from Jackfruit, ricin from castor beans, and Morniga-G [13]. Some of
these lectins displayed some cytotoxicity toward tumor cells in vitro, especially the lectins with
a ribosome inactivating domain or type 2 ribosome-inactivating proteins (RIPs). Obviously, lectins
with RIP-activity, like ricin, abrin, or ebulin, are highly toxic for both healthy and cancer cells, mainly
by inhibiting their protein synthesis. Consequently, these lectins could be used as toxic compounds in
targeted cancer therapy, e.g., for immunotoxin manufacturing [29–32]. Other Gal/GalNAc-specific
plant lectins like PNA (Peanut agglutinin), SBL (Soybean lectin), and VVLB4 (Vicia villosa isolectin B4),
can also induce cell death but their toxicity is at least 1000 times lower than that of ricin and abrin [13].
Moreover, they trigger autophagy, necrosis, or apoptosis in different human carcinoma cells, and these
lectin-induced cell deaths are associated with various biochemical signals, such as the generation of
Reactive oxygen species ROS or caspase activation [33–36].
In Jurkat cells, activation of caspases 8, 9, and 3, and cleavage of PARP accompanying the
Morniga-G treatment, suggest an involvement of both intrinsic and extrinsic pathways in the
Morniga-G-induced cell death. First, Morniga-G elicits both a caspase 9-dependent cell death,
the reversal of mitochondrial membrane potential, and an increase in total ceramides, which is
in agreement with an activation of an intracellular intrinsic pathway (Figure 3). Furthermore, we have
previously shown that FITC-Morniga-G was quickly endocytosed by Jurkat cells (<5 min), making
the lectin readily available for possible intracellular effects [16]. Second, the Morniga-G-induced
cytotoxicity was inhibited in FADD- and caspase 8–10-deficient Jurkat cells, suggesting an activation
of the death receptor pathways by the lectin using FADD and caspase 8. Jurkat cells are known to
express TNF, FasL, and TRAIL receptors and to respond positively to both cytokines. Among these
three types of receptors, only DR5 TRAIL-receptors possess putative sites for O-glycosylation, namely
well-exposed Ser and Thr residues [18,20]. In addition, Jurkat cells are known to express DR5 but
not DR4 [19]. Accordingly, the resistance of leukemic cells to Morniga-G-mediated cytotoxicity after
treatment with anti-DR5 and anti-TRAIL blocking mAbs, strongly suggests an involvement of the
TRAIL/DR5 pathway in cell death. However, this protection was only partial, as compared to
TRAIL-mediated cytotoxicity (Figure 4B), suggesting that other mechanisms might be triggered after
treatment of Jurkat cells with the lectin. Thus, Morniga-G could interact with T/Tn antigens or other
Gal/GalNac residues on TNF receptor I (CD120a) or FasL (CD95), or other glycoproteins distinct
from the cell death receptors, but triggering a rapid release of TNF, FasL, or TRAIL. In this respect,
it was previously shown that a treatment of Jurkat T cells with PHA or an anti-CD59 mAb, induces the
release of TRAIL, TNF, and FasL cytokines, to mediate the so-called “activation-induced cell death”
process [37]. In addition, some activating glycoproteins are known to be sufficiently O-glycosylated
to initiate cell death in proliferating or activated lymphocytes, e.g., CD45 and CD7 [2,38,39], both
expressed in Jurkat T cells. Another interesting pathway, the O-glycosylation of CD7, has also been
described as a target for human galectin-1, a β-galactoside binding lectin. The binding of galectin-1
can induce cell death in both T-lymphoma cells and healthy activated T cells [40].
Both the binding and endocytosis of Morniga-G in Jurkat cells is inhibited by adding inhibitory
sugars, e.g., Gal, GalNAc, or Tn antigen, or O-glycosylated glycoproteins, e.g., the bovine serum
mucin, prior to the lectin [16,17]. Accordingly, our results suggest that Morniga-G-mediated toxicity
depends on some O-glycan recognition, most probably Tn antigen recognition. From our results,
it is tempting to speculate that Tn recognition by the lectin can elicit lymphocyte cell death by
cross-linking of non-FADD dependent receptors like CD45 or CD7 [2,38,39]. However, our results
suggest that TRAIL/DR5 pathway plays a major role in the Morniga-G-induced cell death of Jurkat
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cells. As hypothesized by in silico docking experiments, the interaction of Morniga-G with Tn antigen
haptens located on DR5 in the TRAIL/DR5 complex, could favor the building of TRAIL/DR5 lattices
or increase their efficiency in the TRAIL-mediated apoptotic cell death [20–22].
In conclusion, evidently it is difficult to predict that the Morniga-G lectin will be useful in the
cancer human treatment from these in vitro data alone. However, the present results show that non-RIP
lectins able to specifically recognize aberrations in O-glycosylation, could serve as cytotoxic molecules
against cancer cells. In addition, these lectins offer some exciting new carriers for improving the drug
targeting in cancer treatment [13].
4. Materials and Methods
4.1. Cell Lines and Reagents
Parental Jurkat A3 leukemia cell line (from ATCC, Manassas, VA, U.S.), FADD-deficient Jurkat
cells (∆ FADD, from Dr. J. Blenis, Boston, MA, USA), caspase 9-deficient Jurkat cells (∆ 9, from
Dr. K. Shulze-Osthoff, Düsseldorf, Germany), and Caspase 8- and 10-doubly deficient Jurkat cells
(∆ casp 8–10, from our laboratory [41]), were cultured in RPMI medium containing 10% FCS. Peripheral
blood mononuclear cells (PBMC) were separated using Ficoll-Paque Plus (Amersham Biosciences,
Piscataway, NJ, USA) density gradient and cultured in RPMI containing 10% FCS.
Concanavalin A (Con A) was purchased from Vector Laboratories (Burlingame, CA, USA).
Morniga-G (MorG) and Morniga-M (MorM) were purified from the bark of a black mulberry tree
(Morus nigra), as previously described [7]. Morniga-G was labelled with FITC (Acros Organics,
Fisher Scientific, Illkirch, France) as previously described [16].
The pan-caspases inhibitor z-VAD(OMe)-fmk was purchased from Bachem (Voisins-Le-Bretonneux,
France) and benzyl-2-acetamido-2-desoxy-α-D-galactopyranoside (benzyl-GalNAc) from Merck
(Darmstadt, Deutschland) city, state abbreviation if USA or Canada, country). TRAIL was purchased from
PeproTech (Neuilly-Sur-Seine, France)(city, state abbreviation if USA or Canada, country) and FasL was
produced from Neuro2A cells transfected with a plasmid encoding FasL [41].
Anti-CD175 (anti-Tn) mouse monoclonal antibody (mAb) was purchased from Acris Antibodies
GmbH (Herford, Germany) and fluorochrome-conjugated rat anti-mouse polyclonal antibodies from
Thermo scientific (1 µg/mL), and PE-conjugated anti-human DR5 from Abcam (Cambridge, UK).
Human recombinant blocking monoclonal antibodies anti-DR5 (1 µg/mL) and anti-TRAIL (1 µg/mL)
were purchased from Diaclone (Besançon, France), and anti-Fas (1 µg/mL) from Bender MedSystems
(Vienna, Austria).
Allophycocyanin APC-conjugated anti-CD19 mAb was purchased from Dako (Glostrup, Denmark).
APC-conjugated anti-CD56, FITC-conjugated anti-CD25 mAbs were from Pharmingen (San Diego,
CA, USA). Different fluorochrome-labelled anti-CD3 or anti-CD14 mAbs were from Becton Dickinson
(Franklin Lakes, NJ, USA).
4.2. Human Peripheral Blood Cell Culture, Proliferation, and Activation Assays
PBMCs were isolated from healthy donors using Ficoll-Paque Plus (Amersham Biosciences,
Piscataway, NJ, USA) density gradient centrifugation at 2000 rpm for 20 min. Routinely in PBMC,
lymphocytes were in the range of 80–90%, whereas monocytes (CD14-positive cells) ranged from
10–20%, as evaluated using cytofluorometry. The cells (106 cells/mL) were cultured in triplicate in U
bottom 96-well plates (100 mL/well) or in 24-well plates (1 mL/well) in RPMI 1640 supplemented with
10% fetal calf serum (Gibco, Cergy-Pontoise, France). For proliferation assays, Morniga-M, Morniga-G
and Con A, were added at different concentrations ranging from 2.5 to 25 µg/mL. Subsequently,
cells were incubated for 72 h at 37 ◦C in a 5% CO2 humidified atmosphere, and [3H]-Thymidine
(5µCi/well) (ICN, Orsay, France) was added for the final 16 h of incubation. The content of the
plates was harvested onto a glass fibre filter using a 96 well automatic cell harvester (Harvester 96
Tomtec, Wallac-EG&G instruments, Evry, France) and the [3H]-Thymidine incorporation was measured
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by liquid scintillation counting (Wallac, PerkinElmer, Waltham, CA, USA). Proliferation indexes of
triplicates were calculated from the ratio mean counts per min (cpm) of experimental assay/negative
control. Lectin-triggered lymphocyte activation was assessed after incubation for 72 h in the presence
of lectins at concentrations yielding maximum proliferation. These concentrations were 5 µg/mL
(0.075 mM) for Morniga-M, and 10 µg/mL for Con A (0.1 mM) and Morniga-G (0.14 mM). Naive or
lectin-activated lymphocytes were washed with Phosphate Buffer Saline PBS (pH 7.4), pelleted by
centrifugation at 1400 rpm for 5 min, and then stained at 4 ◦C. Specific activation of lymphocyte
subsets (T cells, B cells, and NK cells) was checked after 72 h cell culture (as described above) by
adding a mixture of labelled antibodies (PerCP anti-CD3,/FITC anti-CD25, APC anti-CD19/FITC
anti-CD25 or APC anti-CD56/FITC anti-CD25), for 30 min in the dark. Then, cells were washed with
PBS (pH 7.4) and re-suspended in 300 µL of PBS (pH 7.4, 1% PFA). Twin CD receptor expression was
monitored by a FACSCan flow cytometer (BD Biosciences, Franklin Lakes, New Jersey, USA) city, state
abbreviation if USA or Canada, country), in a gate corresponding to lymphocytes as defined by the
size and granularity parameters.
4.3. Cell Surface Binding Experiments
Cells (106/mL) were incubated with FITC-Lectin (0.25 µg/mL), anti-Tn antibody (1 µg/mL),
or PE-conjugated anti-DR5 antibody (1 µg/mL) for 30 min at 4 ◦C in PBS. Cells were washed and
stained with PE-conjugated secondary antibody for 30 min at 4 ◦C in PBS. After washing, cells were
analyzed using flow cytofluorometry. Concerning O-glycosylation inhibition assays, benzyl-GalNAc
was added in the culture medium for 72 h at 8 mM before performing cell surface binding experiments
or cytotoxicity assays.
4.4. Lectin-Mediated Cytotoxicity Assay and Cell Death Evaluation
Briefly, Jurkat leukemic T cells (A3, ∆ 9, ∆ FADD, or ∆ casp 8–10) were exposed to Morniga-G
(20 µg/mL) for 24 h in RPMI-SVF 10% at 37 ◦C/5% CO2 humidified atmosphere. In some experiments,
the parental Jurkat A3 leukemia cells were pre-treated (2 h) or not with pan-caspases inhibitor
zVAD (20 µg/mL), or pre-treated (72 h) with the O-glycosylation inhibitor benzyl-GalNAc (8 mM)
then co-incubated with Morniga-G. For blocking assays, anti-DR5 and/or anti-TRAIL neutralizing
antibodies were used. TRAIL (50 ng/mL) or mouse FasL (50 ng/mL) were used as control cell death
assays. Cell death was then estimated by: (i) 3-(4,5-dimethylthiazol)-2-5-diphenyl terazolium bromide
(MTT) reduction method (Euromedex, Souffelweyersheim, France), and (ii) flow cytofluorometry
analysis using annexin V-FITC/propidium iodide (PI) staining (AbCys, Paris, France). The cell death
was determined, after debris exclusion.
Cell death morphology was analyzed using Syto 13 (Molecular Probes, Eugene, OR, USA) and PI
staining with a fluorescence-equipped microscope (Olympus, SELI, Toulouse, France) as previously
described [41].
For mitochondrial analysis, cells were cultivated with lectins for 24 h and cell viability and
mitochondrial membrane potential (mitopotential) were analyzed by Muse Annexin V and Dead Cell
Assay kit (#MCH100105) and Muse MitoPotential Kit (#MCH100110), using Muse Cells Analyzer
(Merckmillipore) (Merck, Darmstadt, Deutschland).
4.5. SDS-PAGE and Western Blot Analysis
Western blots were performed as described elsewhere [41]. Briefly, Jurkat A3 cells were cultured
for different incubation periods (4, 6, or 24 h) in the presence or absence of the lectin. Protein extracts
(20 µg) were separated on SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and
blotted on nitrocellulose membranes. The blots were analyzed using anti-cleaved PARP, anti-cleaved
Caspase-9, -3, and -8 (Cell Signaling Technology, Danvers, MA, USA) or anti-ß Actin (Sigma,
Saint-Quentin Fallavier, France) antibodies.
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4.6. Ceramide Measurement
Ceramide mass was determined as previously reported [42], using recombinant DAG kinase
(kind gift from Drs. D Perry and YA Hannun; Charleston, NC, USA). Briefly, lipids were extracted and
solubilized before DAG kinase assay. Lipid content was then separated by thin layer chromatography,
and ceramide-1-32Phosphate was quantified by phosphor imaging.
4.7. In Silico Molecular Modeling and Docking Experiments
Homology modeling of Morniga-G was performed with the YASARA Structure program [43],
using the X-ray coordinates of the closely related Man-specific lectin Morniga-M (PDB code
1XXR) [44], as a template. Although the homotetrameric model built up for Morniga-G exhibited
a three-dimensional structure closely similar to that of Morniga-M, it differs from the template by the
single-chain structure of the four protomers forming the Morniga-G homotetramer. PROCHECK [45],
ANOLEA [46], and the calculated QMEAN score [47,48], were used to assess the geometric and
thermodynamic qualities of the three-dimensional model. Using ANOLEA to evaluate the model,
18 residues (out of 155) of the model exhibited an energy over the threshold value. Most of these
residues were mainly located at the N-terminal end in the four protomers forming the homotetrameric
structure of Morniga-G. However, the calculated QMEAN4 score gave an acceptable value of −0.85.
Docking of Tn antigen to the monosaccharide-binding site Morniga-G was performed with the
YASARA structure program. Some docking experiments were performed at the SwissDock web server
(http://www.swissdock.ch) [49,50] as a control for our docking experiments. Molecular cartoons were
drawn with Chimera [51].
4.8. Statistical Analyses
Results are expressed as the means ± SD of data obtained from at least three independent
experiments. Statistical significance was determined by means of Student’s t-test. p < 0.05 was
considered significant.
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Abbreviations
Cosmc Core 1 b3-Gal-T-specific molecular chaperone
DISC Death-inducing signaling complex
DR4 Death receptor 4
DR5 Death receptor 5
FADD Fas-associated adaptor protein with a death domain
FCS Fetal calf serum
FITC Fluorescein isothiocyanate
mAb Monnoclonal antibody
Morniga-G Gal-specific black mulberry (Morus nigra) lectin
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NK Natural killer
PARP Poly (ADP-Ribose) polymerase
PBL Peripheral blood lymphocytes
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PBMC Peripheral blood mononuclear cells
PE Phycoerythrin
PI Propidium iodide
PS Phosphatidylserine
T antigen Galb1-3GalNAca1-O-Ser/Thr, i.e., CD176
Tn antigen GalNAca1-O-Ser/Thr, i.e., CD175
TACA Tumor-associated carbohydrate antigens
TNF Tumor necrosis factor
TRAIL Tumor-necrosis-factor related apoptosis inducing ligand
zVAD-fmk N-Benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethyl ketone
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